| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2004;78:1207-1214
© 2004 The Society of Thoracic Surgeons
a Department of Thoracic and Cardiovascular Surgery, University of Virginia, Charlottesville, Virginia, USA
Accepted for publication April 5, 2004.
* Address reprint requests to Dr Jones, Department of Surgery, Box 800679, University of Virginia, Charlottesville, VA, USA 22908-0679
djones{at}virginia.edu
Presented at the Fortieth Annual Meeting of The Society of Thoracic Surgeons, San Antonio, TX, Jan 26–28, 2004.
BACKGROUND: My colleagues and I have previously shown that chemotherapy activates the antiapoptotic transcription factor nuclear factor (NF)-
B in non–small-cell lung cancer (NSCLC). We hypothesized that inhibition of NF-B by using the proteasome inhibitor bortezomib (Velcade) would sensitize NSCLC to gemcitabine-induced apoptosis.
METHODS: Tumorigenic NSCLC cell lines (H157 and A549) were treated with nothing, gemcitabine, bortezomib, or both compounds. NF-B activity was determined by nuclear p65 protein levels, electrophoretic mobility shift assays, and reverse transcription-polymerase chain reaction of the NF-B–regulated genes interleukin-8, c-IAP2, and Bcl-xL. The p21 and p53 protein levels were determined in similarly treated cells. Cell-cycle dysregulation was assessed by fluorescence-activated cell sorting analysis. Cell death and apoptosis were quantified by clonogenic assays, caspase-3 activation, and DNA fragmentation. NSCLC A549 xenografts were generated and treated as noted previously. Tumor growth was assessed over a 4-week treatment period. Statistical analysis was performed with analysis of variance.
RESULTS: Gemcitabine enhanced nuclear p65 levels, NF-B binding to DNA, and transcription of all NF-B–regulated genes. Bortezomib inhibited each of these effects. Combined gemcitabine and bortezomib enhanced p21 and p53 expression and induced S-phase and G2/M cell-cycle arrests, respectively. Combined treatment killed 80% of the NSCLC cells and induced apoptosis, as determined by caspase-3 activation (p = 0.05) and DNA fragmentation (p = 0.02). NSCLC xenografts treated with combination therapy grew significantly slower than xenografts treated with gemcitabine alone (p = 0.02).
CONCLUSIONS: Bortezomib inhibits gemcitabine-induced activation of NF-B and sensitizes NSCLC to death in vitro and in vivo. This combined treatment strategy warrants further investigation and may represent a reasonable treatment strategy for select patients with NSCLC given the current clinical availability of both drugs.
This article has been cited by other articles:
|
|
 |
|
  A. Marten, N. Zeiss, S. Serba, S. Mehrle, M. von Lilienfeld-Toal, and J. Schmidt Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma Mol. Cancer Ther., November 1, 2008; 7(11): 3624 - 3631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Mendler, J. Kelly, S. Voci, D. Marquis, L. Rich, R. M. Rossi, S. H. Bernstein, C. T. Jordan, J. Liesveld, R. I. Fisher, et al. Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma Ann. Onc., October 1, 2008; 19(10): 1759 - 1764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Colado, S. Alvarez-Fernandez, P. Maiso, J. Martin-Sanchez, M. B. Vidriales, M. Garayoa, E. M. Ocio, J. C. Montero, A. Pandiella, and J. F. San Miguel The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype Haematologica, January 1, 2008; 93(1): 57 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Yu, B. B. Friday, L. Yang, P. Atadja, D. Wigle, J. Sarkaria, and A. A. Adjei Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells Neuro-oncol, January 1, 2008; 10(3): 309 - 319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Davies, P. N. Lara Jr., P. C. Mack, and D. R. Gandara Incorporating Bortezomib into the Treatment of Lung Cancer Clin. Cancer Res., August 1, 2007; 13(15): 4647s - 4651s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Dreicer, D. Petrylak, D. Agus, I. Webb, and B. Roth Phase I/II Study of Bortezomib Plus Docetaxel in Patients with Advanced Androgen-Independent Prostate Cancer Clin. Cancer Res., February 15, 2007; 13(4): 1208 - 1215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ceruti, A. Mazzola, and M. P. Abbracchio Proteasome Inhibitors Potentiate Etoposide-Induced Cell Death in Human Astrocytoma Cells Bearing a Mutated p53 Isoform J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1424 - 1434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Fanucchi, F. V. Fossella, R. Belt, R. Natale, P. Fidias, D. P. Carbone, R. Govindan, L. E. Raez, F. Robert, M. Ribeiro, et al. Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., November 1, 2006; 24(31): 5025 - 5033. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Yu, B. B. Friday, J.-P. Lai, L. Yang, J. Sarkaria, N. E. Kay, C. A. Carter, L. R. Roberts, S. H. Kaufmann, and A. A. Adjei Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol. Cancer Ther., September 1, 2006; 5(9): 2378 - 2387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Denlinger, B. K. Rundall, and D. R. Jones Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo J. Thorac. Cardiovasc. Surg., November 1, 2005; 130(5): 1422 - 1429. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
